BICYCLE THERAPEUTICS PLC

• ⚠

  Annual accounts overdue

  Due 2026-06-30.

Figures converted to GBP from USD at 0.749 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

1. BICYCLE THERAPEUTICS PLC 2019-05-22 → present
2. BICYCLE THERAPEUTICS LIMITED 2017-10-27 → 2019-05-22

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“At 31 December 2024, the Company had cash and cash equivalents of $879.5 million and the directors estimate the Company's existing cash and cash equivalents at the date of approval of these financial statements is sufficient to continue to fund the Company's operating expenses for the foreseeable future at least 12 months from the date of that approval and that is therefore appropriate to prepare these financial statements on a going concern basis.”

Group structure

1. BICYCLE THERAPEUTICS PLC · parent
   1. BicycleTx Limited 100% · United Kingdom · Research and development of novel bicyclic peptides
   2. BicycleRD Limited 100% · United Kingdom · Research and development of novel bicyclic peptides
   3. Bicycle Therapeutics Inc. 100% · United States · Research and development of novel bicyclic peptides

Significant events

• “In February 2024, we announced that our Phase II/III Duravelo-2 registrational trial for zelenectide pevedotin in metastatic urothelial cancer was active and recruiting patients, providing multiple opportunities for potential accelerated approval.”
• “In May 2024, we entered into a securities purchase agreement with various investors pursuant to which we sold 6,764,705 ADSs, representing the same number of ordinary shares, nominal value £0.01 per share, and 19,169,001 non-voting ordinary shares, nominal value £0.01 per share, each at a purchase price equal to $21.42 per share. The transaction resulted in gross proceeds of $555.5 million.”
• “In October 2024, we announced the presentation of the first human imaging data validating the potential of MT1-MMP as a novel target in the treatment of cancer and demonstrating the positive properties of BRC molecules for radiopharmaceutical use, as well as preclinical data demonstrating optimised BRC radioisotope delivery.”
• “In December 2024, we announced the presentation of data showing the enhanced anti-tumour activity of zelenectide pevedotin monotherapy in breast cancer patients with NECTIN4 gene amplification as well as topline zelenectide pevedotin monotherapy in non small cell lung cancer patients with NECTIN4 gene amplification. We also announced our plans to advance our development strategy leveraging NECTIN4 gene amplification, with Phase I/II trials in breast cancer, lung-cancer and multiple tumour types planned for 2025.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

15

last 12 months

Capital events

13

last 24 months

Officers appointed

3

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.